Johns Hopkins Medicine Office of Continuing Medical Education
Course Calendar Programs Registration Faculty Online Post Tests Home
Contact us
Traveling to CME
Answers to your questions
Resources for planners
CME Online
Find a course

Advanced search
    The Implications of Natalizumab for Multiple Sclerosis (MS) Therapy

Course Director: Douglas A. Kerr, MD, PhD
January 18, 2005 - January 18, 2006

The approval of natalizumab for the treatment of MS presents MS-treating physicians and nurses with another therapy in their MS armamentarium. Recently released data from the Phase III natalizumab AFFIRM trial demonstrates a reduction in the risk of exacerbation by 66% in the first year of therapy, presenting a significant improvement over current MS therapies. This educational activity presents the natalizumab Phase III data and provides an expert discussion and Q&A; about the implications natalizumab may have for the treatment of MS, including infusion therapy and indications for use, alone and in combination with existing disease modifying therapies.

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physicians' Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Click here to to participate in this online CME activity


©2002-2003, Johns Hopkins University, School of Medicine, Office of Continuing Medical Education
Privacy statement | Website design: Kim Bieler Graphic Design